Cetuximab Activity in Dysplastic Lesions of the Upper Aerodigestive Tract

BACKGROUND: High risk head and neck mucosal premalignancy has a malignant conversion rate of up to 40%, despite adequate surgical therapy. Epidermal Growth Factor Receptor (EGFR) blocking agents, including cetuximab, have shown activity in head and neck squamous cell carcinoma (HNSCC) and have poten...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oral Oncol
Autors principals: Khan, Zubair, Epstein, Joel B, Marur, Shanthi, Gillespie, M Boyd, Feldman, Lawrence, Tsai, Hua-Ling, Zhang, Zhe, Wang, Hao, Sciubba, James, Ferris, Robert, Grandis, Jennifer R, Gibson, Michael, Koch, Wayne, Tufano, Ralph, Westra, William, Tsottles, Nancy, Ozawa, Hiroyuki, Chung, Christine, Califano, Joseph A
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7751887/
https://ncbi.nlm.nih.gov/pubmed/26686755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2015.11.016
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars